AirSculpt Technologies, Inc. Common Stock Canaccord Genuity's 46th Annual Growth Conference

Susan, thank you so much, and thank you for having us at the conference. It's great to be here. Folks, just a quick bit about AirSculpt. We're a premier body contouring company. What that means is we do plastic surgery procedures, particularly around fat removal, fat transfer, and skin tightening. We have 31 centers in North America where we do these procedures. All procedures are minimally invasive. The patient is awake during the procedure as well, and you're back home within a few hours. Many people are back to their normal routine within 24 to 48 hours. So in that sense, very effective and minimally invasive. Average procedure is about $12,000 to $13,000. It's all cash pay, so that implies a certain demographic. Our patients tend to be more affluent, leaning more towards women.

For us, we're seeing tremendous opportunity both in the fat removal, fat transfer, skin tightening space, but also with GLP-1s. People are looking for more aesthetic solutions which can help them complete their journey. So overall, it's a great business model, great margins, and we're really excited to be here.

Absolutely. Just for context, our business has stabilized over the last couple of quarters to positive case growth. That's a trend change that we've been able to implement. What is really driving that is a few things. One, as I've joined over the last year and a half or so, we brought in new talent, which has strengthened the company. We've revamped our sales and marketing execution, which is really driving a lot of the top line. We're also just operating and executing with a lot of discipline. That's what's carried us through, and the results are showing with the second consecutive quarter of stability after many quarters of decline.

Yeah, absolutely. First and foremost, for those who don't know, obviously everyone talks about selling GLP-1s and the impact of GLP-1s. There's a lot of people trying to sell GLP-1s. We are one of the scaled players out there who can address the side effects of GLP-1s. If someone goes on the drug over 6, 12, 18 months, the biggest side effects tend to be loose skin, and then stubborn fat deposits. You lost the weight, but now you have loose skin. You lost the fat, but you also lost volume along with that.

Our core procedure helps with those already.

We saw an opportunity to expand our procedures to get into skin excisions. We've expanded that to our centers as well around how we reduce skin excision so that if there's excess loose skin from certain areas, we can take it out. Beyond that, in body contouring, just yesterday, we announced a partnership with Tiger Aesthetics for alloClae. That's for volume restoration, so that's donor-derived fat.

Okay. If somebody doesn't have enough of their own fat to transfer, they can get donor-derived fat, which can be injected into their body.

Okay. All of that to serve the needs of GLP-1 patients to restore volume and to address loose skin.

The traction's been really good. We started with standalone skin tightening late last year, middle of last year, and in the quarter we just announced, we did about 200 procedures related to skin removal. That's roughly mid to high single digits of our total procedure count.

That's been growing quarter-over-quarter. That's what we've been- Wow.